Lipohypertrophy (LH) & Fibrosis: The Epidemic Undermining Glycemic Control Circle - Arrow Right

64% of insulin users develop LH at injection sites, impairing insulin absorption, raising A1Cs and threatening outcomes.

Active Site Care

Diagram of the compression patch with indicator lines pointing to the applicator and patch.

The first-ever compression patch to demonstrate statistically significant clinical results remodeling LH & fibrosis.

Without Embrace®

Crossection of tissue indicating the trauma.

Repetitive microtraumas activate LH and scar tissue formation.

With Embrace® (Mechanism of Action)

Crossection of tissue showing the shrink process - step 1. Crossection of tissue showing the shrink process - step 2

embrace® actively shrinks to compress the site, controlling the healing environment and minimizing site damage.

Patented & Clinically Proven

Our patented tension offloading technology downregulates fibroblasts, reducing inflammation and the production of adipose tissue. embrace® protects delivery sites and helps support consistent insulin absorption.

Preserve Skin

Prolong Site Use

Protect Outcomes
FDA 510(k) Cleared
• CE Marked •
OTC Available Now

embrace® Proven to Remodel Long-Standing Lipohypertrophy Tension offloading technology delivers statistically significant results Circle - Arrow Right

Active Site Care

Groundbreaking Clinical Results

~20% Reduction LH Volume Vs. Untreated Ultrasound Evidence LH Volume Reduction Embrace chart showing volume change 6.97X Improvement Fat Remodeling Biopsy Evidence Fat Development Improvement Embrace chart showing fat improvement

Patient
Outcomes

  • 37% Self-reported using less insulin to effectively manage their blood glucose.
  • 48% Cited improved insulin absorption and 33% had better blood glucose.
  • 78% Patient satisfaction with embrace® after 16 weeks of use.

Clinical trial conducted at Profil Institute for Metabolic Research.